# Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

> **NCT02120300** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 122 (actual)

## Conditions studied

- Chronic HCV Infection

## Interventions

- **DRUG:** LDV/SOF
- **DRUG:** SOF
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT02120300
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2016-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02120300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02120300, "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02120300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*